ReviewNanomedicine (London, England)2012
Cancer stem cells and drug resistance: the potential of nanomedicine.
Review in Nanomedicine (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 200 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
200 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cancer Stem Cell Biomarkers Predictive of Radiotherapy Response in Rectal Cancer: A Systematic Review.Genes · 2021Pooled it
- Quantitative assessment of CD44 genetic variants and cancer susceptibility in Asians: a meta-analysis.Oncotarget · 2016Pooled it
- A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients.Journal of nanobiotechnology · 2019Trial
- Current therapeutic interventions to target cancer stem cells for metastasis.International journal of clinical oncology · 2026Review
- Precision Nanotechnology: Revolutionizing Therapeutic Strategies Against Drug-Resistant Breast Cancer.Annals of biomedical engineering · 2026Review
- Defective biological networks associated with pseudogene-derived lncRNAs in cancer drug resistance: Promising prospects for their clinical targets in cancer therapy.Genes & diseases · 2026Review
- Designing polyphosphazene derivatives for gene delivery in glioblastoma treatment.Materials today. Bio · 2025Article
- Recent advancements in genistein nanocarrier systems for effective cancer management.Medical oncology (Northwood, London, England) · 2025Review
- Evaluation of Notch1 and CD10 Expressions in Colorectal Carcinoma and Their Relationship with Prognosis.Iranian journal of pathology · 2025Article
- Prognostic and Immunologic Significance of SH2B2 in Colon Adenocarcinoma and its Relationship to Proliferation, Migration, and Invasion.Combinatorial chemistry & high throughput screening · 2025Article
- Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy.Cancer cell international · 2024Review
- MUC1-EGFR crosstalk with IL-6 by activating NF-κB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma.Annals of medicine · 2024Article
- DLK1 Is Associated with Stemness Phenotype in Medullary Thyroid Carcinoma Cell Lines.International journal of molecular sciences · 2024Article
- Plant-Based Anticancer Compounds With a Focus on Breast Cancer.Cancer reports (Hoboken, N.J.) · 2024Review
- A protracted war against cancer drug resistance.Cancer cell international · 2024Review
- Article
- Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance.Cancer metastasis reviews · 2024Review
- Combined Effects of Annexin A5 Overexpression, 5-Fluorouracil Treatment, and Irradiation on Cell Viability of Caski Cervical Cancer Cell Line.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Deciphering lung adenocarcinoma prognosis and immunotherapy response through an AI-driven stemness-related gene signature.Journal of cellular and molecular medicine · 2024Article
- Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.Journal of nanobiotechnology · 2024Article
140 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Properties of the small group of cancer cells called tumor-initiating or cancer stem cells (CSCs) involved in drug resistance, metastasis and relapse of cancers can significantly affect tumor therapy. Importantly, tumor drug resistance seems to be closely related to many intrinsic or acquired properties of CSCs, such as quiescence, specific morphology, DNA repair ability and overexpression of antiapoptotic proteins, drug efflux transporters and detoxifying enzymes. The specific microenvironment (niche) and hypoxic stability provide additional protection against anticancer therapy for CSCs. Thus, CSC-focused therapy is destined to form the core of any effective anticancer strategy. Nanomedicine has great potential in the development of CSC-targeting drugs, controlled drug delivery and release, and the design of novel gene-specific drugs and diagnostic modalities. This review is focused on tumor drug resistance-related properties of CSCs and describes current nanomedicine approaches, which could form the basis of novel combination therapies for eliminating metastatic and CSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.